StreetInsider.com News Articles

Form 4 MANNKIND CORP For: Jul 15 Filed by: Prentiss Christopher B

Fri, 17 Jul 2026 21:48:00 -0400

si-local-file:///var/storage/secattach/20260717/26785538.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Prentiss Christopher B

Fri, 17 Jul 2026 21:48:00 -0400

si-local-file:///var/storage/secattach/20260717/26785538.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Marasco Dominic

Fri, 17 Jul 2026 21:47:00 -0400

si-local-file:///var/storage/secattach/20260717/26785537.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Marasco Dominic

Fri, 17 Jul 2026 21:47:00 -0400

si-local-file:///var/storage/secattach/20260717/26785537.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Castagna Michael

Fri, 17 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26785532.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Castagna Michael

Fri, 17 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26785532.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Tross Stuart A

Fri, 17 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26785534.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Tross Stuart A

Fri, 17 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26785534.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Thomson David

Fri, 17 Jul 2026 21:44:00 -0400

si-local-file:///var/storage/secattach/20260717/26785529.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Thomson David

Fri, 17 Jul 2026 21:44:00 -0400

si-local-file:///var/storage/secattach/20260717/26785529.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Singh Sanjay R

Fri, 17 Jul 2026 21:44:00 -0400

si-local-file:///var/storage/secattach/20260717/26785530.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Singh Sanjay R

Fri, 17 Jul 2026 21:44:00 -0400

si-local-file:///var/storage/secattach/20260717/26785530.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Binder Steven B.

Fri, 17 Jul 2026 21:43:00 -0400

si-local-file:///var/storage/secattach/20260717/26785527.html

Form 4 MANNKIND CORP For: Jul 15 Filed by: Binder Steven B.

Fri, 17 Jul 2026 21:43:00 -0400

si-local-file:///var/storage/secattach/20260717/26785527.html

Form 144 MANNKIND CORP Filed by: Thomson David

Fri, 17 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260717/26784622.html

Form 144 MANNKIND CORP Filed by: Thomson David

Fri, 17 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260717/26784622.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 17 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260717/26784616.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 17 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260717/26784616.html

MannKind receives Breakthrough T1D grant for pediatric Afrezza trial

Tue, 23 Jun 2026 09:00:15 -0400

MannKind Corporation (Nasdaq: MNKD) has received a grant from Breakthrough T1D, formerly known as JDRF, to support its INHALE-1ST clinical trial evaluating inhaled insulin Afrezza in pediatric patients newly diagnosed with type 1 diabetes.

The grant was awarded through Breakthrough T1D's Industry Discovery and Development Partnership program. The INHALE-1ST study is a single-arm, multi-center trial assessing the safety and efficacy of Afrezza in combination with once-daily subcutaneously injected basal insulin in patients aged 10 to under 18 years who have been recently diagnosed with type 1 diabetes.

The trial's primary endpoint is the percentage of participants achieving a continuous glucose monitor time-in-range

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Tue, 23 Jun 2026 09:00:00 -0400

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced it has been awarded a grant from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes (T1D) research and advocacy organization, through its Industry Discovery and Development Partnership (IDDP) program, to support the ongoing INHALE-1^ST clinical study

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Tue, 23 Jun 2026 09:00:00 -0400

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Tue, 23 Jun 2026 09:00:00 -0400

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Tue, 23 Jun 2026 09:00:00 -0400

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation